SG&A Expense Trends: A Tale of Two Biotechs

In the dynamic world of biotechnology, understanding financial trends is crucial for investors and stakeholders. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent biotech companies: Dynavax Technologies Corporation and Merus N.V., from 2014 to 2023.

Dynavax Technologies Corporation

Dynavax has shown a remarkable upward trajectory in its SG&A expenses, growing by approximately 760% over the decade. This increase reflects the company's aggressive expansion and investment in its operational capabilities. Notably, from 2021 to 2023, Dynavax's expenses surged by 53%, indicating a strategic push in its business operations.

Merus N.V.

Merus N.V., on the other hand, has experienced a more moderate increase of around 1,450% in SG&A expenses over the same period. The company's steady growth suggests a balanced approach to scaling its operations, with a notable 17% rise from 2022 to 2023.

These trends highlight the contrasting strategies of these biotech firms, offering valuable insights for potential investors.